🚀 In our massive specialization feature in our even bigger Q4 2024 edition of Protein Production Technology International, Dr Olivia Ogilvie, CEO of New Zealand-based Opo Bio, uses an agricultural metaphor to simplify her work in cultivated meat:
“We develop cell lines—these are analogous to seeds. If you don’t have good seeds, it’s hard to produce products at scale,” she explains.
Opo Bio focuses on creating high-quality cell lines, enabling other companies to succeed in scaling cultivated meat production. Olivia believes specialization across the supply chain can accelerate commercialization, particularly in the current challenging funding environment.
Olivia acknowledges the shift in investor sentiment but remains confident in the long-term potential of cultivated meat as a deep-tech field with longer commercialization timelines.
She stresses the importance of addressing the technical challenges and not underselling the difficulty of bringing products to market. Despite industry hurdles, Opo Bio’s specialized approach has attracted investors, securing NZ$1.5 million in seed capital just months after its 2022 launch.
Olivia remains optimistic, stating, “The best is yet to come.”
🤓 Hear more from Olivia and Opo Bio in the latest edition of Protein Production Technology International: https://hubs.ly/Q02_fk1m0
#CellularAgriculture #CultivatedMeat #AlternativeProtein #Innovation #Sustainability
